Clinical Trial

Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease

Name: Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease — clinical trial record (NCT07280299)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The purpose of this study is to assess the efficacy, the safety, and the effect on biomarkers of 2 dose levels of oral GT-02287 over placebo after 48 weeks of treatment in treated and untreated participants with early PD.

Trial Details

NCT Number	NCT07280299
Lead Sponsor	Gain Therapeutics, Inc.
Conditions	Parkinson Disease
Enrollment	111 participants
Start Date	2026-05-30
Primary Completion	2028-06-30 (estimated)
Study Completion	2028-06-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-12